Esteve Healthcare (ESTEVE) has commenced 2024 with a renewed Board of Directors, aiming to continue driving sustainability and future growth. These changes follow Lubea's entry into the shareholding in September 2023. In adherence to good governance practices, the revised Board composition not only enhances diversity but also assembles a seasoned and diverse group.

Recognized for their accomplishments in expanding businesses and augmenting value for both the organization and society, this board is poised to play a pivotal role in shaping the strategic direction for ESTEVE and actively contributing to its continuous growth. The newly appointed Board Directors are as follows:

Jane Griffiths, assuming her position on ESTEVE's Board on January 1st, brings over 30 years of invaluable experience to the healthcare industry. Griffiths leadership extends to past roles where she led the European Federation of Pharmaceutical Industries and Associations and the PhRMA Europe Committee, showcasing her commitment to women's leadership and sustainability. This strategic addition aligns with ESTEVE's dedication to diverse and seasoned leadership.

Griffiths succeeds Jesús Caínzos, who leaves the Board after years of dedicated collaboration. "We extend our gratitude to Jesús Caínzos for his enduring commitment to ESTEVE; his instrumental contributions and exemplary work on the Board are duly acknowledged" Albert Esteve, Chairman of the Board of Directors, stands out. Jacques Tapiero, independent director of the Board since 2017 now assumes the pivotal role of Lead Director.

Ewald Walgenbach, who became part of the board in November 2023, brings a unique perspective with his PhD in Genetics/Biochemistry from the Max Planck Institute and his consulting experience at BCG, focusing on the pharmaceutical sector. His extensive leadership experience, including a significant role at Bertelsmann and a partnership at BC Partners specializing in healthcare, adds depth to his current board positions at Aenova and Springer Nature.

Wolfram von Braunschweig, joined the Board in October 2023. In his role as Managing Director of Lubea, he has many years of experience in managing investments and a background in corporate and investment banking. He studied economics and history in Heidelberg and Freiburg and holds an MBA from INSEAD in Fontainebleau.

Nick Bohn, who also joined the Board in October 2023, is Lubea's Managing Director. He leverages his broad expertise in healthcare investments, building on his experience in European mergers and acquisitions at Roland Berger. He has a Master's Degree in Quantitative Economics from the University of St. Gallen and studied Economics in Lüneburg, Madrid and Seoul.

Since redefining its strategic plan in 2018, ESTEVE has adeptly expanded its specialty pharma product portfolio, flawlessly executing its strategic roadmap. In 2023, to foster additional growth and facilitate international expansion, ESTEVE announced a strategic partnership with Lubea, a German private investment firm. Lubea acquired a 26% minority stake in ESTEVE, injecting capital into the company. With the new Board of Directors composition, the company is ready to take new steps towards its ambition of becoming a leading international specialty pharmaceutical company.

View full details in our website: https://www.esteve.com/global/about-us/corporate-governance